Knowledge of previously unknown genes for new enzymes and proteins of commercial interests in the C1 genome is expected to help the company accelerate its own product development, as well as to allow it to assist a variety of agricultural, chemical, pharmaceutical, personal care, diagnostic and other companies to develop novel products to meet their needs.
The sequencing of the C1 genome is expected to enable the company to mine the estimated 10,000 - 15,000 genes in the C1 genome for many more new product opportunities for its own products and for its business collaborators' product lines. For example, the research funds spent on reprogramming the C1 Host Organism may also help the company in the future to discover, develop and produce antibodies and other therapeutic proteins for curing human diseases.
"In the first quarter of 2005, we continued our transition to a public company and focused on laying the foundation for future growth," said Mark Emalfarb, Dyadic's President and CEO. "Prior to raising capital last year, Dyadic was resource constrained. So, we had to make some hard choices. Two new products from this initiative have already been launched and others are in various stages of development. As a result, we expect to accelerate the launch of new products to the market in the months and years ahead."
"We also recruited a CFO, made several other key hires, including a Vice President for Pulp & Paper Enzymes, and added experienchers are in various stages of development. As a result, we expect to accelerate the launch of new products to the market in the months and years ahead."
marketing@alchempro.com
